BIOMAT Database Logo BIOMAT Database Logo

Observations on dibromodulcitol (DBD)-mitolactol-treatment. 1977

G Perényl, and K Büttner, and L Dénes

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008936 Mitolactol Alkylating antineoplastic toxic to bone marrow; used in breast cancer, also in combination with other drugs. Dibromodulcitol,NSC-104800,NSC 104800,NSC104800
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

G Perényl, and K Büttner, and L Dénes
Effect of Mitolactol (Dibromodulcitol) treatment in bladder cancer.
January 1978, Therapia Hungarica (English edition),
G Perényl, and K Büttner, and L Dénes
Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man. I. Metabolites of DBD.
March 1979, European journal of cancer,
G Perényl, and K Büttner, and L Dénes
Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man--II. pharmacokinetics of DBD.
November 1982, European journal of cancer & clinical oncology,
G Perényl, and K Büttner, and L Dénes
Effect of 1,6-dibromodulcitol (DBD) on the RNA metabolism of S37 tumour cells.
January 1973, Acta biologica Academiae Scientiarum Hungaricae,
G Perényl, and K Büttner, and L Dénes
BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas.
January 2002, Neoplasma,
G Perényl, and K Büttner, and L Dénes
A phase II study of dibromodulcitol (DBD) in stage IV melanoma.
October 1984, American journal of clinical oncology,
G Perényl, and K Büttner, and L Dénes
Results obtained with Dibromodulcitol (DBD) in the therapy of upper respiratory tract tumours.
January 1974, Therapia Hungarica (English edition),
G Perényl, and K Büttner, and L Dénes
Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.
April 1985, American journal of clinical oncology,
G Perényl, and K Büttner, and L Dénes
Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP).
January 1981, Cancer treatment reports,
G Perényl, and K Büttner, and L Dénes
Pharmacokinetics and metabolism of dianhydrogalactitol DAG in patients: a comparison with the human disposition of dibromodulcitol DBD.
February 1986, European journal of cancer & clinical oncology,
Copied contents to your clipboard!